Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

(2017) John J. Bissler et al.   PLoS One

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study

(2016) David N. Franz et al.   PLoS One

Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus

(2015) Neera Nathan et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in Tuberous Sclerosis Complex

(2014) R. Balestri et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Dermatologic and Dental Aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements

(2014) Joyce M. C. Teng et al.   JAMA Dermatology

Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer

(2013) Parvin F. Peddi et al.   CANCER TREATMENT REVIEWS

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

(2013) John J Bissler et al.   LANCET

Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference

(2013) Darcy A. Krueger et al.   PEDIATRIC NEUROLOGY

Mammalian Target of Rapamycin Inhibitors Induce Tumor Cell ApoptosisIn VivoPrimarily by Inhibiting VEGF Expression and Angiogenesis

(2013) Patrick Frost et al.   Journal of Oncology

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

(2012) David Neal Franz et al.   LANCET

Tuberous Sclerosis Complex–Associated Angiomyolipomas: Focus on mTOR Inhibition

(2011) Klemens Budde et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial

(2011) D. M. Davies et al.   CLINICAL CANCER RESEARCH

Tuberous Sclerosis Complex: Neurological, Renal and Pulmonary Manifestations

(2011) D. N. Franz et al.   NEUROPEDIATRICS

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

(2011) Francis X. McCormack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease

(2011) Sandra L. Dabora et al.   PLoS One

Sirolimus and Everolimus Induced Pneumonitis in Adult Renal Allograft Recipients: Experience in a Center

(2009) A. Rodríguez-Moreno et al.   TRANSPLANTATION PROCEEDINGS

The TSC1–TSC2 complex: a molecular switchboard controlling cell growth

(2008) Jingxiang Huang et al.   BIOCHEMICAL JOURNAL

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis

(2008) G.F.L. Hofbauer et al.   BRITISH JOURNAL OF DERMATOLOGY

Tuberous sclerosis

(2008) Paolo Curatolo et al.   LANCET

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

(2008) John J. Bissler et al.   NEW ENGLAND JOURNAL OF MEDICINE